Holen Sie sich die Stockscreener-App
8.475
0.32%
-0.005
Schlusskurs vom Vortag:
$8.48
Offen:
$8.43
24-Stunden-Volumen:
195.94K
Relative Volume:
0.11
Marktkapitalisierung:
$1.55B
Einnahmen:
$314.85M
Nettoeinkommen (Verlust:
$12.01M
KGV:
129.39
EPS:
0.0655
Netto-Cashflow:
$47.52M
1W Leistung:
-1.48%
1M Leistung:
+6.60%
6M Leistung:
+50.95%
1J Leistung:
+10.07%
1-Tages-Spanne:
$8.37
$8.605
1-Wochen-Bereich:
$8.22
$8.775
52-Wochen-Spanne:
$5.25
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
8.475 | 1.55B | 314.85M | 12.01M | 47.52M | 0.0655 |
TAK
Takeda Pharmaceutical Co Adr
|
18.30 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.89 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.165 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.48 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
496.47 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
XERS Looks 54.7% Overvalued on GF Value™ as Clinical Update Appr - GuruFocus
Millions of thyroid patients may get weekly shot option from Xeris (NASDAQ: XERS) - Stock Titan
An estimated 3 to 5 million lack thyroid control. Xeris is developing a weekly injection. - Stock Titan
Xeris Biopharma Holdings Inc. (XERS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares By Investing.com - Investing.com South Africa
Xeris Biopharma CFO Steven Pieper sells $42,500 in shares - Investing.com
Xeris Biopharma COO Kevin McCulloch sells $127,308 in stock By Investing.com - Investing.com Nigeria
Xeris Biopharma’s Beth Hecht sells $141,434 in company stock - Investing.com
Xeris Biopharma CFO Steven Pieper Executes Sale of 5,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma CLO Beth Hecht Sells 16,666 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma COO Kevin McCulloch Sells 15,000 Shares via 10b5-1 Trading Plan - Kalkine Media
Xeris Biopharma Holdings Inc. (XERS) Peer Comparison – Compare with Others - Value Research
Xeris Biopharma stock holds at $8.48 after earnings miss - AD HOC NEWS
Xeris Biopharma Holdings Inc. (XERS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Xeris Biopharma Holdings, Inc. (0A8E.L) Stock Price, News, Quote & History - Yahoo Finance
Xeris Announces Details for XP-8121 Program Overview Webinar - Yahoo Finance
XERS | Xeris Biopharma Holdings, Inc. FinancialsRevenue Breakdown - quiverquant.com
Xeris Biopharma CEO John Patrick Shannon Jr. Reports Share Withholding for RSU Tax Settlement - Kalkine Media
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Xeris Biopharma posts record $203M revenue in 2... - Pluang
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move - vinanet.vn
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Sahm
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS Q2 2026 Earnings: Steep EPS Miss Weighs on SharesFinancial Summary - vinanet.vn
XERS|Xeris Biopharma Holdings Inc|Price:8.500|Chg%:-0.100 - TradingKey
XERS Q2 2026 Earnings: Significant EPS Miss Weighs on SharesRevenue Per Share - Vinanet
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS - webull.com
HC Wainwright Expects Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) options chain – Yahoo Finance - Yahoo Finance Singapore
Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Sahm
Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Stock News Today - TradingKey
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors - DirectorsTalk Interviews
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call High - GuruFocus
XERS Looks 53.1% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary - TradingView
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Sep 01 '26 |
Sale |
8.49 |
16,666 |
141,434 |
1,127,796 |
| Pieper Steven | See Remarks |
Sep 01 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,356,053 |
| Pieper Steven | See Remarks |
Aug 12 '26 |
Sale |
8.50 |
5,000 |
42,500 |
1,361,053 |
0.30%
0.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):